IMMATICS NV

Immatics NV: German biotech driving cancer immunotherapy breakthroughs, trading on Frankfurt with a €1.45 bn market cap and a negative P/E reflecting R&D‑heavy growth.

Immatics NV, a German biotech company, has made significant strides in cancer immunotherapy with its IMA203 PRAME cell therapy, showing promising clinical outcomes in treating metastatic melanoma.